In a phase 3 trial of 593 patients with IPF, inhaled treprostinil versus placebo for 52 weeks gave a smaller FVC decline (difference 95.6 ml; median -49.9 vs -136.4 ml) and less clinical worsening (27.2% vs 39.0%); cough was 48.3% vs 24.1%.
RCTn = 593
Nathan et al. Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis